DR REDDYS LABORATORIES LTD

Form 6-K

February 01, 2019
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February 2019
Commission File Number 1-15182
DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x	Form 40-F "	
Indicate by check mark if the reginal 101(b)(1):	strant is submitting the Form 6-K is	n paper as permitted by Regulation S-T Rule
Note: Regulation S-T Rule 101(b) provide an attached annual report		paper of a Form 6-K if submitted solely to
Indicate by check mark if the regint 101(b)(7):	strant is submitting the Form 6-K in	n paper as permitted by Regulation S-T Rule
report or other document that the injurisdiction in which the registrant under the rules of the home country other document is not a press release.	registrant foreign private issuer mu t is incorporated, domiciled or lega ry exchange on which the registran ase, is not required to be and has no	paper of a Form 6-K if submitted to furnish a st furnish and make public under the laws of the lly organized (the registrant's "home country"), of t's securities are traded, as long as the report or be to been distributed to the registrant's security ject of a Form 6-K submission or other
-	·	ined in this Form, the registrant is also thereby -2(b) under the Securities Exchange Act of 1934
Yes " No x		
If "Yes" is marked, indicate below 82	v the file number assigned to regist	rant in connection with Rule 12g3-2(b):

DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

We hereby furnish the United States Securities and Exchange Commission with copies of the following information about our public disclosures regarding our results of operations and financial condition for the quarter and nine months ended December 31,2018.

On February 01, 2019, we announced our results of operations for the quarter and nine months ended December 31, 2018. We issued a press release announcing our results under International Financial Reporting Standards ("IFRS"), IFRS Unaudited Consolidated Financial Results with review report, Ind AS Unaudited Consolidated Financial Results with review report and Ind AS Unaudited Standalone Financial Results with review report for the quarter and nine months ended December 31, 2018, a copy of which is attached to this Form 6-K as Exhibit 99.1, 99.2, 99.3 and 99.4 respectively.

We have also made available to the public on our web site, www.drreddys.com, the following: IFRS Unaudited Consolidated Financial Results, Ind AS Unaudited Consolidated Financial Results and Ind AS Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2018.

Exhibits

Exhibit Number	Description of Exhibits
99.1	Press Release, "Dr. Reddy's Q3 FY19 Financial Results", February 01, 2019
99.2	IFRS Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2018
99.3	Ind AS Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2018
<u>99.4</u>	Ind AS Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DR. REDDY'S LABORATORIES LIMITED (Registrant)

Date: February 01, 2019 By: /s/ Sandeep Poddar

Name: Sandeep Poddar Title: Company Secretary